Muneeb Z. Niazi

Jul 19, 2024 | survivornet.com | Muneeb Z. Niazi

According to a study, Black women reach the national average risk for breast cancer at age 42. Thus, it may be reasonable to start screenings at 42 for Black women. The risk for breast cancer differs between different racial groups. Black women tend to get breast cancer earlier and may develop more aggressive diseases. Current breast cancer screening guidelines, which recommend starting regular breast cancer screenings at age 45 or 50, may need to be modified for Black women.

Feb 3, 2024 | survivornet.com | Muneeb Z. Niazi

The start of the COVID-19 pandemic led to stay-at-home orders and triage guidelines that caused delays in cancer screenings in the United States. This led to a 14.4% decline in cancer detection in 2020. This translates into more than 200,000 “missing” cases of new cancers. These "missing" cases are likely to present at more advanced stages in the future, when they are less curable.

Aug 30, 2023 | survivornet.com | Muneeb Z. Niazi

A drug called epcoritamab (brand name: Epkinly) has been approved for the treatment of diffuse large B-cell lymphoma (DLBCL). While generally treatable, some cases of DLBCL can be treatment-resistant or can return after an initial cure. These can be a challenge to treat. Epkinly is a bispecific antibody that brings the cancerous B cells into contact with T-cells, which can eliminate cancers.

Jul 16, 2023 | survivornet.com | Laura Gesualdi |Elizabeth Comen |Muneeb Z. Niazi |James Taylor

The American Society of Clinical Oncology (ASCO) has issued a new recommendation that some women with advanced breast cancer be tested for a mutation in the ESR1 gene. The recommendation comes after the approval of a drug called elacestrant (Orserdu) earlier this year. The drug showed promise in treating people whose tumors were ER-positive, HER2-negative, had the ESR1 mutation, and had continued to grow after hormone therapy.

Jul 16, 2023 | survivornet.com | Laura Gesualdi |Elizabeth Comen |Muneeb Z. Niazi |James Taylor

ASCO Issues New Recommendation for ESR1 TestingThe American Society of Clinical Oncology (ASCO) has issued a new recommendation that some women with advanced breast cancer be tested for a mutation in the ESR1 gene. The recommendation comes after the approval of a drug called elacestrant (Orserdu) earlier this year. The drug showed promise in treating people whose tumors were ER-positive, HER2-negative, had the ESR1 mutation, and had continued to grow after hormone therapy.